Vol. 151 No. 0304 (2021)
Retrospective analysis of adverse drug reactions leading to short-term emergency hospital readmission
AIMS OF THE STUDY
Adverse drug reactions (ADRs) are an important cause of hospital admissions. Insufficient data are available about the frequency and characteristics of ADR-related emergency readmissions in Switzerland. The aim of this retrospective study was to characterise ADRs related to short-term emergency readmissions in a large Swiss University Hospital and to assess their reporting frequency.
Electronic records of all patients discharged from the University Hospital Bern within a 12-month period (1 January to 31 December 2012) and emergency readmission within 30 calendar days were reviewed. Case inclusion required a known ADR. Cases with intentional overdosing, lack of compliance or insufficient documentation were excluded. Identified ADR-related readmission cases were searched in the Swiss ADR reporting system to assess reporting rate.
There were 1294 emergency readmissions among the 4792 readmissions (14% of all admissions) within 30 days after discharge. We identified 270 cases of ADR-related readmissions, corresponding to 21% of emergency readmissions and 6% of all readmissions within 30 days. The most frequent ADRs were gastrointestinal disorders (26%), infections and infestations (19%), and nervous system disorders (10%). The most frequent drug classes leading to ADRs were antineoplastic/immunomodulating (35%) and antithrombotic agents (25%). Only 8 (3%) of the 270 cases were reported to the Swiss ADR reporting system.
ADR-related readmissions constituted a considerable part of short-term emergency readmissions. Despite being a relevant cause for rehospitalisation, only a minority of the ADRs were reported to the regulatory authorities. Strategies to prevent ADR-related readmissions and to improve reporting rates are needed.
- Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9. doi:.https://doi.org/10.1016/S0140-6736(00)02799-9
- Fattinger K, Roos M, Vergères P, Holenstein C, Kind B, Masche U, et al. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49(2):158–67. doi:.https://doi.org/10.1046/j.1365-2125.2000.00132.x
- Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998;45(3):301–8. doi:.https://doi.org/10.1046/j.1365-2125.1998.00667.x
- Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993;27(7-8):832–40. doi:.https://doi.org/10.1177/106002809302700702
- Hallas J, Worm J, Beck-Nielsen J, Gram LF, Grodum E, Damsbo N, et al. Drug related events and drug utilization in patients admitted to a geriatric hospital department. Dan Med Bull. 1991;38(5):417–20.
- Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301–6. doi:.https://doi.org/10.1001/jama.1997.03540280039031
- El Morabet N, Uitvlugt EB, van den Bemt BJF, van den Bemt PMLA, Janssen MJA, Karapinar-Çarkit F. Prevalence and Preventability of Drug-Related Hospital Readmissions: A Systematic Review. J Am Geriatr Soc. 2018;66(3):602–8. doi:.https://doi.org/10.1111/jgs.15244
- Davies ECGC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol. 2010;70(5):749–55. doi:.https://doi.org/10.1111/j.1365-2125.2010.03751.x
- Teymoorian SS, Dutcher D, Woods M. Association between postdischarge adverse drug reactions and 30-day hospital readmission in patients aged 80 and older. J Am Geriatr Soc. 2011;59(5):948–9. doi:.https://doi.org/10.1111/j.1532-5415.2011.03376.x
- Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Tröger M, Azaz-Livshits T, et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med. 2004;255(6):653–63. doi:.https://doi.org/10.1111/j.1365-2796.2004.01326.x
- World Health Organization. Available at: https://www.who.int/en/. Last accessed: September 2020.
- Swissmedic. Pharmacovigilance. Available at: https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/pharmacovigilance.html. Last accessed: October 2020.
- Schwab C, Korb-Savoldelli V, Escudie JB, Fernandez C, Durieux P, Saint-Jean O, et al. Iatrogenic risk factors associated with hospital readmission of elderly patients: A matched case-control study using a clinical data warehouse. J Clin Pharm Ther. 2018;43(3):393–400. doi:.https://doi.org/10.1111/jcpt.12670
- Swissmedic. Arzneimittelinformation-Publikationssystem (AIPS). Switzerland. Available at: http://www.swissmedicinfo.ch. Last accessed: January 2018.
- Micromedex® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com/. Last accessed: January 2018
- WHO Collaborating Centre for Drug Statistics Methodolgy. ATC/DDD Index 2019. Available at: https://www.whocc.no/atc_ddd_index/. Last accessed: January 2018.
- Pharmavista - Information for healthcare professionals. Available at: www.pharmavista.ch/content/default.aspx. Last accessed: January 2018.
- MedDRA Maintenance and Support Services Organization. Introductory Guide MedDRA Version 14.0 2011. Available at: https://www.who.int/medical_devices/innovation/MedDRAintroguide_version14_0_March2011.pdf. Last accessed: January 2018.
- Schweizerische Gesellschaft für Klinische Pharmakologie und Toxikologie. Grundlagen der Arzneimitteltherapie. Documed; 2005.
- The Uppsala Monitoring Centre. The use of the WHO-UMC sytsem for standardised case causality assessment. Available at: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Last accessed: September 2020.
- Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program [published correction appears in N Engl J Med. 2011 Apr 21;364(16):1582]. N Engl J Med. 2009;360(14):1418–28. doi:.https://doi.org/10.1056/NEJMsa0803563
- Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12. doi:.https://doi.org/10.1056/NEJMsa1103053
- National Committee for Quality Assurance (NCQA). Healthcare Effectiveness Data and Information Set (HEDIS). 2011. Available at: https://www.ncqa.org/.
- Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147(11):755–65. doi:.https://doi.org/10.7326/0003-4819-147-11-200712040-00006
- Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24. doi:.https://doi.org/10.1001/archinte.163.22.2716
- Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev. 2013;34(1):15–38.
- Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31-32):543–51. doi:.https://doi.org/10.3238/arztebl.2010.0543
- Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med. 2012;172(14):1057–69. doi:.https://doi.org/10.1001/archinternmed.2012.2246
- Mekonnen AB, McLachlan AJ, Brien JA. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016;6(2):e010003. doi:.https://doi.org/10.1136/bmjopen-2015-010003
- Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al.; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–79. doi:.https://doi.org/10.1056/NEJMoa0706135
- Schoonover H, Corbett CF, Weeks DL, Willson MN, Setter SM. Predicting potential postdischarge adverse drug events and 30-day unplanned hospital readmissions from medication regimen complexity. J Patient Saf. 2014;10(4):186–91. doi:.https://doi.org/10.1097/PTS.0000000000000067
- Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556–64. doi:.https://doi.org/10.1056/NEJMsa020703
- Chayé H, Bernard M, Tubéry M, Rousseau V, Ecoiffier M, Montastruc JL, et al. Réhospitalisations d’origine médicamenteuse : étude pilote dans un service de post-urgences médicales d’un hôpital universitaire français [Hospital readmission induced by adverse drug reaction: a pilot study in a post-emergency unit of a French university hospital]. Rev Med Interne. 2015;36(7):450–6. doi:.https://doi.org/10.1016/j.revmed.2014.11.016
- Güner MD, Ekmekci PE. Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. J Drug Assess. 2019;8(1):13–20. doi:.https://doi.org/10.1080/21556660.2019.1566137
- Centers for Medicare and Medicaid Services. Hospital Redamission Reduction Program (HRRP). Available at: https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program. Last accessed: September 2020.
- Kristensen SR, Bech M, Quentin W. A roadmap for comparing readmission policies with application to Denmark, England, Germany and the United States. Health Policy. 2015;119(3):264–73. doi:.https://doi.org/10.1016/j.healthpol.2014.12.009